Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) Short Interest Down 27.2% in January

Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) saw a large decrease in short interest during the month of January. As of January 15th, there was short interest totaling 5,444 shares, a decrease of 27.2% from the December 31st total of 7,478 shares. Currently, 0.0% of the shares of the stock are sold short. Based on an average trading volume of 56,787 shares, the short-interest ratio is currently 0.1 days. Based on an average trading volume of 56,787 shares, the short-interest ratio is currently 0.1 days. Currently, 0.0% of the shares of the stock are sold short.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Barinthus Biotherapeutics stock. Baird Financial Group Inc. increased its position in Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) by 108.2% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 192,461 shares of the company’s stock after purchasing an additional 100,000 shares during the period. Baird Financial Group Inc. owned 0.48% of Barinthus Biotherapeutics worth $179,000 at the end of the most recent quarter. Institutional investors own 25.20% of the company’s stock.

Barinthus Biotherapeutics Trading Down 0.4%

NASDAQ BRNS traded down $0.00 during trading hours on Monday, reaching $0.73. The company had a trading volume of 18,713 shares, compared to its average volume of 39,989. The stock has a market capitalization of $29.68 million, a P/E ratio of -0.39 and a beta of -0.66. The stock has a 50-day moving average of $0.73 and a 200 day moving average of $1.07. Barinthus Biotherapeutics has a 1-year low of $0.64 and a 1-year high of $2.92.

Barinthus Biotherapeutics (NASDAQ:BRNS) last posted its earnings results on Friday, November 7th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.09. As a group, sell-side analysts predict that Barinthus Biotherapeutics will post -1.38 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the company. HC Wainwright upped their price target on Barinthus Biotherapeutics from $3.00 to $4.00 and gave the company a “buy” rating in a research report on Monday, November 17th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Barinthus Biotherapeutics in a research note on Monday, December 22nd. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $4.00.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.